News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Depomed, Inc. (DEPO) , Biovail Corporation (BVF) Update Status Of Glumetza NDA



10/19/2005 5:13:16 PM

MENLO PARK, Calif.--(BUSINESS WIRE)--April 13, 2005--Depomed, Inc. (NASDAQ:DEPO) and Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that a response has been submitted to the United States Food and Drug Administration (FDA) regarding an outstanding inquiry on the New Drug Application (NDA) for Glumetza(TM), a once-daily, extended-release formulation of metformin hydrochloride (HCl) for the treatment of Type II diabetes. Last month, the companies announced that the NDA for Glumetza was deemed "Approvable" by the FDA, pending the resolution of an issue related to finalizing a manufacturing specification. This issue was addressed in a response which was filed at the FDA on April 8, 2005. Depomed and Biovail believe that the response will be considered as a Class I response, which carries a 60-day review period. Within 30 days of final approval, Biovail will make a $25 million milestone payment to Depomed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES